News

When a Vaccine Safety Trial Becomes Unethical
New vaccines are often evaluated in trials in which some participants receive a placebo. But not all studies can be designed ...
Targeted Oncology2d
FDA Oks Phase 3 Trial of PT-112 in mCRPC Following Successful EOP2 Meeting
PT-112 monotherapy advances to phase 3 trial in metastatic castration-resistant prostate cancer after positive FDA end of ...
Trial finds benefits of 16-hour fasting are evident for at least 1 year, regardless of eating window timing
Three months of time-restricted eating (TRE), irrespective of whether it is earlier or later in the day, may be a promising ...
Managed Healthcare Executive16h
Gene Therapy Elevidys Slows Motor Decline In Boys With Duchenne, Phase 3 Trial Shows
Developed by Sarepta Therapeutics, Elevidys is a one-time, intravenous treatment that uses adeno-associated virus (AAV) ...
Applied Clinical Trials Online1d
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A.
Investing.com South Africa3d
Moderna stock soars on FDA booster trial plans
Shares of vaccine makers saw an uptick in the latest trading session, with Moderna Inc (BMV:MRNA). (NASDAQ:MRNA) leading the ...
The Bakersfield Californian1d
Rubedo Life Sciences Announces First Patient Dosed with Lead Drug Candidate RLS-1496, the First GPX4 Modulator Targeting Pathologic Senescent Cells To Enter Phase 1 Clinical Trial
We are excited to reach this important milestone not only for our lead candidate RLS-1496 but also for the advancement of longevity science,” said Rubedo CEO Frederick Beddingfield, III, MD, PhD, FAAD ...
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)
Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled ...
Pharmabiz1d
Accropeutics reports positive data from phase 2 trial of AC-201, an oral, selective TYK2/JAK1 inhibitor, to treat moderate-to-severe plaque psoriasis
Accropeutics reports positive data from phase 2 trial of AC-201, an oral, selective TYK2/JAK1 inhibitor, to treat moderate-to-severe plaque psoriasis: New York Thursday, May 22, 2 ...